Cancer ResearchPersonalized Immune Therapy Reduces Melanoma Recurrence After Surgery
A personalized immune treatment helped keep high-risk melanoma from returning after surgery in a large randomized trial. Researchers assigned 1,137 patients to receive intismeran autogene or placebo, with both groups receiving pembrolizumab. After two years, 82.2% of patients receiving the combination were alive without cancer recurrence, compared with 70.0% receiving pembrolizumab plus placebo. Freedom from distant cancer spread was also higher, at 88.5% versus 80.2%. Benefits emerged after six months rather than immediately. Severe or worse adverse events occurred in 23.6% versus 20.3% of patients. Eight patients in the combination group died from adverse events, including five before receiving intismeran; this does not establish that intismeran caused those deaths. These findings support further clinical consideration, but longer overall survival remains unproven. This summary is based on the abstract only.